Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 4 Effect of CRME on Liver function test

From: Promising anitidiabetic potential of Cuscuta reflexa leaves methanol extract in alloxan-induced diabetic rats

Groups Liver function test
  ALT (U/l) ALP(U/l) AST(U/l) Bilirubin (mg/dl)
Group I 51.95 ± 2.4 35.50 ± 3.1 105.50 ± 3.9 0.49 ± 0.04
Group II 79.50 ± 3.7a** 87.70 ± 4.1a** 226.45 ± 6.9a** 1.39 ± 0.07a**
Group III 73.15 ± 3.0 80.45 ± 4.3 195.08 ± 5.4b* 1.28 ± 0.06
Group IV 60.55 ± 3.9b* 70.55 ± 4.1b* 135.15 ± 6.6b** 0.75 ± 0.03b**
Group V 55.40 ± 3.3b* 54.80 ± 3.1b** 96.45 ± 4.1b** 0.63 ± 0.04b**
Group VI 49.25 ± 3.7b** 39.35 ± 3.8b** 71.19 ± 3.4b** 0.57 ± 0.02b**
  1. All values were expressed as mean ± S.E.M (n = 3). (*) indicates statistically significant difference from the respective group (**p < 0.01) whereas (η) indicates statistically no significant difference from the respective group (p > 0.05) using ANOVA, followed by Dunnett’s multiple comparison test. a = while compared with healthy control, b = while compared with diabetic control. Group I = Healthy control, Group II = Diabetic control, Group III = Diabetic control + 10 mg/kg of gliclazide, Group IV = Diabetic control + 100 mg/kg CRME, Group V = Diabetic control + 200 mg/kg CRME, Group VI = Diabetic control + 400 mg/kg CRME